Health & Biotech
Incannex Healthcare Limited (IHL.ASX) is a clinical stage pharmaceutical development company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of Generalised Anxiety Disorder (GAD), Obstructive Sleep Apnoea (OSA), Traumatic Brain Injury (TBI)/Concussion, rheumatoid arthritis, inflammatory bowel disease and inflammatory lung conditions (ARDS, COPD, Asthma, Bronchitis).
FDA registration and marketing approval, subject to ongoing clinical success, is being pursued for each product and therapy under development.
Each indication represents major global markets and currently have either no, or limited, existing registered pharmacotherapy (drug) treatments available to the public, raising the possibility of patients receiving Government subsidies for products that demonstrate suitable safety and efficacy profiles in clinical trials.
Incannex has a strong patent filing strategy as it develops its products and therapies in conjunction with its medical and scientific advisory board and its collaborative partners, including Monash University and The Alfred Hospital.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Weed Week: Ice-T plans to open dispensary and Snoop Dogg’s venture capital firm backs weed snacks
Health & Biotech
Incannex powers into addiction treatment following APIRx deal to takeover novel patented treatments
News
ASX Small Caps Lunch Wrap: Who else is pondering their decision-making today?
Health & Biotech
Incannex completes landmark deal, positioning as a global leader in medicinal cannabis and psychedelics
News
Market highlights and 5 ASX small caps to watch on Friday
Health & Biotech
Incannex Engages Curia to scale-up manufacture of inhaled drug product to treat traumatic brain injury
Health & Biotech
Weed Week: Aurora Marijuanis and CBD bubble tea in Thailand
News
ASX Quarterlies: Records tumble, targets achieved in good news for shareholders
Health & Biotech
Incannex receives key ethics approval to start Phase 1 clinical trial of multi-use anti-inflammatory drug
News
Market highlights and 5 ASX small caps to watch on Thursday
Health & Biotech
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
Experts
MoneyTalks: ASX biotechnology shares are deeply discounted – Paul Hart says ‘perfect time’ to buy
Health & Biotech
Could Aussie cannabinoid companies help solve a global opioid crisis?
Health & Biotech
ASX Health Stocks: Healius tracks guidance, wants to focus on pathology and imaging
Health & Biotech
Weed Week: Woody Harrelson opens weed dispensary and Byron Bay could be home to a cannabis resort
Health & Biotech
Shares in Incannex jump 11% after positive US FDA meet over sleep apnoea drug
Health & Biotech